First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

Despite securing the industry’s first approval for familial chylomicronemia syndrome, BMO Capital Markets believes that ...

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint ...

While layoffs have slowed in the second half of the year, according to BioSpace data, companies including Bayer, Bristol ...

Novo Nordisk executives set a high bar for itself when it projected CagriSema could achieve 25% weight loss. When the GLP-1 ...

Suddenly the hottest thing in biopharma isn’t a new indication, disease target or modality—it’s manufacturing, and all of ...

Novartis, Biogen, Takeda and Novo Nordisk are all betting on advances in the molecular glue degraders space, collectively ...

According to the World Health Organization, GLP-1 receptor agonists are currently being used in a highly medicalized manner.

Vertex Pharmaceuticals’ investigational non-opioid analgesic suzetrigine failed to outperform placebo. Investors voiced their ...

For the second time this week, a Big Pharma–partnered Parkinson’s disease asset has failed in the clinic. This time it’s ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...